



3 December 2015

(15-6397)

Page: 1/2

Committee on Technical Barriers to Trade

Original: English/French

NOTIFICATION

The following notification is being circulated in accordance with Article 10.6

1.	Notifying Member: <u>CANADA</u> If applicable, name of local government involved (Article 3.2 and 7.2):
2.	Agency responsible: Department of Health Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above: Canada's Notification Authority and Enquiry Point Foreign Affairs, Trade and Development Canada Technical Barriers and Regulations Division (TIB) 111 Sussex Drive Ottawa, ON K1A 0G2 Canada Telephone: (343) 203-4273 Fax: (613) 943-0346 Email: enquirypoint@international.gc.ca
3.	Notified under Article 2.9.2 [X], 2.10.1 [], 5.6.2 [], 5.7.1 [], other:
4.	Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable): Prescription status of medicinal ingredients for human use (ICS: 11.120; HS: 3004.90). – Other (HS: 300490)
5.	Title, number of pages and language(s) of the notified document: Notice of Consultation – Prescription Drug List (PDL): Fluticasone Propionate (2 pages, in English and French)
6.	Description of content: The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to revise the listing for Adrenocortical Hormones or their salts or derivatives on the Human Prescription Drug List (PDL) to permit the non-prescription use of Fluticasone propionate for certain uses.
7.	Objective and rationale, including the nature of urgent problems where applicable: Protection of human health or safety
8.	Relevant documents: Health Canada website: http://www.hc-sc.gc.ca/dhp-mpps/consultation/drug-medic/pdl_ldo_consult_fluticasone-eng.php , posted: 27 November 2015 (available in English and French)
9.	Proposed date of adoption: 10 February 2016 Proposed date of entry into force: 10 August 2016
10.	Final date for comments: 10 February 2016

11. Texts available from: National enquiry point [X] or address, telephone and fax numbers and email and website addresses, if available, of other body:

The electronic version of the regulatory text can be downloaded at:

http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/lead_pdl_ldo_consult_fluticasone-eng.php

http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/lead_pdl_ldo_consult_fluticasone-fra.php